ACKR2 and ovarian carcinoma: DPP4 attenuates C-X-C motif ligand 10 (CXCL10) and atypical chemokine receptor 2 (ACKR2) activity by regulating N-terminal processing [15], while DPP4 inhibitors may serve as second-line treatment for epithelial ovarian cancer [16].